Risk of severe breakthrough Covid-19 higher for seniors and people with underlying conditions.
Risk of severe breakthrough Covid-19 higher for seniors and people with underlying conditions – CNN Original study: Hospitalisation among vaccine breakthrough COVID-19 infections – The Lancet Infectious Diseases News release: Study examines severe breakthrough cases of COVID-19 – YaleNews Commentary on Twitter New Comment: Hospitalisation among vaccine breakthrough #COVID19 infections https://t.co/1MtOoO8HVV, by Prerak V […]
The post Risk of severe breakthrough Covid-19 higher for seniors and people with underlying conditions. appeared first on Links Medicus.
What’s the evidence for COVID-19 booster shots?
What’s the evidence for COVID-19 booster shots? – Canadian Medical Association Journal
The post What’s the evidence for COVID-19 booster shots? appeared first on Links Medicus.
Topic-based, recent literature review on pulmonary hypertension.
Topic-Based, Recent Literature Review on Pulmonary Hypertension – Mayo Clinic Proceedings
The post Topic-based, recent literature review on pulmonary hypertension. appeared first on Links Medicus.
Perspective | What we actually know about waning immunity.
What We Actually Know About Waning Immunity – The Atlantic
The post Perspective | What we actually know about waning immunity. appeared first on Links Medicus.
COVID infections may give more potent immunity than vaccines – but that doesn’t mean you should try to catch it.
COVID infections may give more potent immunity than vaccines – but that doesn’t mean you should try to catch it – The Conversation Original study and commentary: [Preprint] Observational data suggests natural immunity after a SARS-CoV-2 infection confers longer lasting and stronger protection compared to vaccine-induced immunity.
The post COVID infections may give more potent immunity than vaccines – but that doesn’t mean you should try to catch it. appeared first on Links Medicus.
Long COVID and kidney disease.
Long COVID and kidney disease – Nature Reviews Nephrology
The post Long COVID and kidney disease. appeared first on Links Medicus.
Covid-19: Infection increases the risk of kidney disease even in mild cases, finds study.
Covid-19: Infection increases the risk of kidney disease even in mild cases, finds study – The BMJ Original study: Kidney Outcomes in Long COVID – Journal of the American Society of Nephrology
The post Covid-19: Infection increases the risk of kidney disease even in mild cases, finds study. appeared first on Links Medicus.
Face masks for COVID pass their largest test yet – “A rigorous study finds that surgical masks are highly protective, but cloth masks fall short”.
Face masks for COVID pass their largest test yet – Nature Original study: [Preprint] Largest study of masks yet details their importance in fighting Covid-19. Commentary on Twitter Face masks for COVID pass their largest test yet – I & others comment. It is true that I bought pink surgical masks (my favorite color) […]
The post Face masks for COVID pass their largest test yet – “A rigorous study finds that surgical masks are highly protective, but cloth masks fall short”. appeared first on Links Medicus.
RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial – Nature Medicine News release: Major study finds convalescent plasma doesn’t help seriously ill COVID-19 patients – McMaster University Related: NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms. M-A: Convalescent plasma is safe but does not […]
The post RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19. appeared first on Links Medicus.
RCT: No benefit from Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis.
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
The post RCT: No benefit from Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis. appeared first on Links Medicus.